In Tuesday’s Wall Street session, Moderna Inc (NASDAQ:MRNA) shares traded at $33.28, down -1.83% from the previous session.
MRNA stock price is now -12.65% away from the 50-day moving average and -56.54% away from the 200-day moving average. The market capitalization of the company currently stands at $12.84B.
With the price target reduced from $111 to $45, Barclays Downgraded its rating from Overweight to Equal Weight for Moderna Inc (NASDAQ: MRNA). On January 29, 2025, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $99 to quote $51, while ‘Argus’ rates the stock as ‘Hold’
In other news, Klinger Shannon Thyme, Chief Legal Officer sold 529 shares of the company’s stock on Dec 09 ’24. The stock was sold for $23,637 at an average price of $44.68. Upon completion of the transaction, the Chief Legal Officer now directly owns 20,446 shares in the company, valued at $0.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09 ’24, Officer Klinger Shannon Thyme bought 529 shares of the business’s stock. A total of $23,637 was incurred on buying the stock at an average price of $44.68. A total of 11.42% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $29.25 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 3.67, and a quick ratio of 3.62.
The net profit margin was -110.04% and return on equity was -28.77% for MRNA. The company reported revenue of $966.0 million for the quarter, compared to $2.81 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -65.64 percent.
